Duration of Intensive Respiratory Support and Risk of Long-term Respiratory Failure in Patients with COVID-19

Ogata, Hiroaki; Jingushi, Yujiro; Katahira, Katsuyuki; Ishimatsu, Akiko; Kotetsu, Yasuaki; Sha, Kachi; Enokizu-Ogawa, Aimi; Taguchi, Kensei; Moriwaki, Atsushi; Yoshida, Makoto

doi:10.2169/internalmedicine.0660-22

Cited by 1 publication

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the pathogenesis of ABPA, biologics designed to target type 2 inflammation, initially developed for severe asthma management, are expected to potentially serve as effective treatment alternatives for ABPA [48]. Although limited by the scarcity of randomized controlled trials, recent case reports and case series have demonstrated the benefits of target type 2 inflammation in the treatment of ABPA [48][49][50][51].…”

Section: Immunobiological Drugsmentioning

confidence: 99%

“…Tezepelumab a human IgG2 monoclonal antibody that binds specifically to thymic stromal lymphopoietin (TSLP) was demonstrated to improve the control of severe asthma by normalizing broad inflammatory pathways [54]. A recently published case report on a patient using mepolizumab, showed benefits in control of symptoms and reduction of the mucus plugs and pulmonary opacities [51].…”

Section: Immunobiological Drugsmentioning

confidence: 99%

See 1 more Smart Citation

Allergic Bronchopulmonary Aspergillosis/Mycosis: An Underdiagnosed Disease

Oliveira Rodrigues Valle,

Sarquis Serpa,

Sarquis Serpa

2023

Infectious Diseases

View full text Add to dashboard Cite

Allergic bronchopulmonary aspergillosis (ABPA) is an immune-allergic disease of the lung due to a hypersensitivity reaction to antigens of Aspergillus fumigatus after colonization into the airways. Predominantly, it affects patients with bronchial asthma and those having cystic fibrosis (CF). Despite being recognized as a distinct entity nearly 70 years ago, this disease remains underdiagnosed. This may be due to the diagnostic methods employed, lack of standardized tests, and diagnostic criteria. The mainstay treatment for ABPA is systemic steroid. Azole antifungal agents represent an alternative for the treatment of exacerbations and are preferential strategy for corticosteroids sparing. Biologic drugs are expected to play an important role in the treatment of ABPA based on their mechanism in inhibition of type 2 inflammation, regulation of eosinophils and IgE levels, and modulation of inflammatory cytokines. Therefore, other studies are necessary for a better understanding of this disease so that an early detection can be done as well as a correct management.

show abstract

Section: Immunobiological Drugsmentioning

confidence: 99%

Section: Immunobiological Drugsmentioning

confidence: 99%